Diabetic macular oedema: evidence‐based treatment recommendations for Asian countries

Diabetic macular oedema is the most common cause of diabetic retinopathy‐induced vision loss. Efficacy of anti‐vascular endothelial growth factor therapy in diabetic macular oedema has been demonstrated in randomized controlled trials. An Asian‐specific guideline for diabetic macular oedema treatment is needed as patients in Asia tend to present with far more advanced disease than seen elsewhere in the world. Previous reviews of diabetic macular oedema management lacked a broader assessment of anti‐vascular endothelial growth factor treatment choices and newer trials. Recent clinical trial data allow head‐to‐head comparisons between the different anti‐vascular endothelial growth factor agents and treatment regimens. This review aims to summarize the clinical evidence related to various treatment regimens for clinicians, with a focus on anti‐vascular endothelial growth factor therapies, and to provide guidance on the treatment of diabetic macular oedema in Asian patients.